Research programme: ovarian tumor imaging agents - Imaginab
Latest Information Update: 28 May 2024
At a glance
- Originator ImaginAb Inc
- Class Antibody diagnostics; Imaging agents
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 28 May 2024 No recent reports of development identified for research development in Ovarian-cancer(Diagnosis) in USA (Parenteral)
- 22 Apr 2020 New Profile created